Surfacing Themes at Access USA 2026

In a conversation with Pharmaceutical Executive, Ankit Jain, CEO, Co-Founder, Infinitus discusses how Infinitus is reimagining patient access through AI, aiming to streamline the patient journey from diagnosis to therapy adherence. Jain notes how Infinitus focuses on reducing friction points like prior authorization and benefit verification, leveraging AI to handle repetitive tasks and empower care teams to provide empathetic care.

A transcript of Jain’s conversation with Pharmaceutical Executive can be found below.

Pharmaceutical Executive: What are some themes that keep surfacing in conversations here at Access USA?
Ankit Jain: There's three themes that are going to come up a lot these next couple of days. The first one is, how does the regulatory environment change? The way in which we design our systems, whether it's the patient support programs, the patient assistance programs, a lot of the dynamics are changing. Suddenly, there's a lot more focused on these groups than there ever was normally.

Pap and PSP were those children of a family that just existed but didn't have the spotlight on them. But with all the movement towards direct to patient movements, every major pharma company now has to think about having contact centers, having groups that can answer questions, 24/7, 365, and the one group that has experience with that is normally the Patient Support Program. It's the is the patient access group. So everyone's looking at them for knowledge and for experience as to how to scale this up to support DTP programs. So that's the first one.

The second one that we're going to hear about is where we can't just keep throwing more butts in seats. The traditional model of the hub is dead. How do we bring technology and people together so we can scale up for three reasons, one, for the DTP part, second because we're seeing more drugs come to market, more indications get approved, and the demands from the modern consumer are very different than the ones from a few years ago.

And then the third thing that we're going to hear about is too many AI vendors, too many point solutions that are doing one thing and doing it decently well. That's too much for pharma to take on. So what are the platforms? Just what are the companies that can really help transform the entire business process for pharmaceutical manufacturers so their patients, their members, their caregivers, their HCPs, can see longitudinally, a cohesive story. It's not a different AI agent or a different human agent touching different parts of the care journey.